BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Schwarz Pharma Announces Publication Of Rotigotine Phase III Data In Neurology


1/4/2007 4:06:19 PM

MONHEIM, Germany, Jan. 3 /PRNewswire/ -- SCHWARZ PHARMA announced today the electronic publication of a pivotal phase III clinical trial in the journal, Neurology. This trial showed positive results of its once daily dopamine agonist, rotigotine, for the treatment of early-stage Parkinson's disease (PD). Rotigotine is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery (through the skin) system. The study, titled "Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease," can be found on Neurology's web site at http://www.neurology.org .

The multi-center, randomized, double-blind study was designed to evaluate the safety and effectiveness of the once-daily dopamine agonist rotigotine, supplied via a once daily transdermal patch that delivers the drug continuously, versus placebo in patients with early-stage PD. The author and lead investigator of the study, Ray L. Watts, MD, Director of Clinical Research and Chairman of Neurology, University of Alabama at Birmingham, concluded that rotigotine, when titrated to a dose of 6mg/24hr, was effective for the treatment of early-stage PD. In addition, rotigotine appeared to be well-tolerated by patients.

"Parkinson's disease is a progressive disorder and this important study showed that rotigotine may be safe and effective, and potentially be of significant value in the treatment of early-stage PD," said Dr. Watts. "Rotigotine is a dopamine agonist that offers continuous drug delivery with a once-daily patch, which will hopefully mitigate the practical intra-day variability that accompanies the multiple dose regimens of other dopaminergic drugs."

Study Design and Results

This phase III clinical trial evaluated 302 patients with early-stage, idiopathic PD at 50 clinical study sites in the United States and Canada. Two hundred seventy-seven patients were randomized to receive placebo (n=96) or rotigotine (n=181). The rotigotine group started treatment with the 2mg/24hr (10 cm squared) patch and titrated weekly up to a maximum dose of 6mg/24hr (30 cm squared). The 27-week study period included a three-week titration phase, followed by a 24-week maintenance phase. There was also a four-week pre-treatment phase and a four-week safety follow-up phase. The primary efficacy measure was the change from baseline in parts II and III of the Unified Parkinson Disease Rating Scale (UPDRS) score, which assesses a patient's ability to perform everyday activities and also evaluates motor symptoms of PD.

Compared with placebo, rotigotine significantly improved patients' symptoms in early-stage PD through six months of therapy as measured by parts II and III of the UPDRS (a decrease in UPDRS scores signifies symptom improvement). Patients in the placebo group had a mean increase in UPDRS subtotals of 1.31 +/- 0.956, while the rotigotine group had a mean decrease in score of 3.98 +/- 0.707 (P < 0.0001). The most commonly reported adverse events (>10 percent) that occurred in patients receiving rotigotine were application site reactions (which were generally mild to moderate in intensity), nausea, somnolence, dizziness, and headache.

About Rotigotine

Rotigotine is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery system, a patch, designed for once-a-day application. Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. Rotigotine is currently under review with the U.S. Food and Drug Administration (FDA) for its efficacy and safety as treatment for early-stage PD. At this time, it is marketed in Europe as monotherapy for early-stage PD and has received a favorable review for advanced-stage PD.

About Parkinson's Disease

Parkinson's disease is a progressive disorder of the central nervous system. The patients -- roughly four million worldwide, including approximately 1 million people in the U.S. -- suffer primarily from a lack of dopamine, a messenger substance in the central nervous system, which is responsible for the coordination of movement. As a result of this shortage, patients are no longer able to control their movements reliably. Dopamine agonists are drugs that attempt to compensate for this lack of dopamine.

SCHWARZ PHARMA (headquartered in Monheim, Germany) is a stock listed company with approximately 4,400 employees worldwide. The company develops novel medicines in the therapeutic areas of the central nervous system. Furthermore it markets innovative drugs focused to treat cardiovascular and gastro-intestinal diseases. In 2005 the SCHWARZ PHARMA group achieved global sales of nearly euro 1 billion. The company has a strong international presence with subsidiaries in Europe, USA and Asia.

This press release contains forward-looking statements based on current plans, estimates and beliefs of the management of SCHWARZ PHARMA AG. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation affecting SCHWARZ PHARMA AG, exchange rate fluctuations and hiring and retention of its employees.

All SCHWARZ PHARMA press releases are distributed by e-mail at the same time they become available on the website. Please go to www.schwarzpharma.com, press room, news subscription to register online, change your selection or discontinue this service.

SCHWARZ PHARMA

CONTACT: Antje Witte, +49-2173-48-1866, or Bettina Ellinghorst,+49-2173-48-2329; or for U.S. inquiries, Michael Davis, +1-262-238-5446,all for SCHWARZ PHARMA



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES